What is DARA Biosciences Financial Strength?
DARA Biosciences has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
GuruFocus does not calculate DARA Biosciences's interest coverage with the available data.
DARA Biosciences's debt to revenue ratio for the quarter that ended in Sep. 2015 was 0.01.
As of today, DARA Biosciences's Altman Z-Score is 0.00.
Competitive Comparison of DARA Biosciences's Financial Strength
For the Biotechnology subindustry, DARA Biosciences's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DARA Biosciences's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DARA Biosciences's Financial Strength distribution charts can be found below:
* The bar in red indicates where DARA Biosciences's Financial Strength falls into.
DARA Biosciences Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
DARA Biosciences's Interest Expense for the
months ended in Sep. 2015 was $0.00 Mil. Its Operating Income for the
months ended in Sep. 2015 was $-2.70 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was $0.02 Mil.
DARA Biosciences's Interest Coverage for the quarter that ended in Sep. 2015 is
| GuruFocus does not calculate DARA Biosciences's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
DARA Biosciences's Debt to Revenue Ratio for the quarter that ended in Sep. 2015 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
DARA Biosciences has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DARA Biosciences (DARA Biosciences) Business Description
Traded in Other Exchanges
N/A
Address
DARA Biosciences Inc was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox (oral liquid tamoxifen). The Company's main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Soltamox has been approved by the U.S. Food and Drug Administration ('FDA') for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company's agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman's gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company's advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.
Executives
| David Drutz |
director, officer: Executive Chairman and CMO |
8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615 |
| David L. Tousley |
officer: CFO |
14610 PAWNEE LANE, LEAWOOD KS 66224 |
| Gail Lieberman |
director |
175 EAST 79TH STREET, APT. 4D, NEW YORK NY 10075 |
| Paul John Richardson |
director |
17 COUNTRY OAKS ROAD, LEBANON NJ 08833 |
| Steve Gorlin |
director |
150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541 |
| Ann A Rosar |
officer: Vice President Finance |
C/O 801 CAPITOLA DRIVE, DURHAM NC 27713 |
| John C Thomas |
director |
8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615 |
| Geert Cauwenbergh |
director |
1 STULTS DRIVE, PLAINSBORO NJ 08536 |
| Kurt M Eichler |
director |
C/O SPRING BANK PHARMACEUTICALS, INC., STE S-7, MILFORD MA 01757 |
| Hamilton Jordan |
director |
|
| Stuart C Mcwhorter |
director |
113 SEABOARD LANE, FRANKLIN TN 37067 |
| Timothy J Barberich |
director |
40 ELM ST, CONCORD MA 01752 |
| Michael P Duffy |
officer: SVP, GC and Secretary |
C/O POINT THERAPEUTICS INC, 125 SUMMER STREET SUITE 1840, BOSTON MA 02110 |
| Richard J Benjamin |
director |
15 WHITE PINE ROAD, NEWTON MA 02464 |
| Larry G Pickering |
director |
26130 MANDEVILLA DRIVE, BONITA SPRINGS FL 34134 |
DARA Biosciences (DARA Biosciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DARA has been successfully added to your